North America News

Latest News
Spotlight on… asset classes in the US (H1 2022)
North America | Industry
16 Sep 2022 by SRP News

There was a significant shift towards products linked to single indices in H1 2022.

SRP Americas 2022 Awards: all the winners
International | Industry
16 Sep 2022 by SRP News

The best in class in the structured products industry gathered on 15 September 2022 in Chicago for the SRP Americas 2022 Awards. The full list of winners is below.

SRP Americas Personality of the Year 2022 – Mike Heraty
North America | Industry
14 Sep 2022 by Pablo Conde

Congratulations to 2022’s SRP Americas Personality of the Year Mike Heraty, the head of Equity Derivative sales for North America at Credit Suisse. He received the most votes in the 2022 Americas awards survey.

UBS to pay US$25m to settle SEC charges, investors seek further compensation
North America | Regulations & Legal
01 Sep 2022 by SRP News

The Swiss bank faces claims of alleged unsuitable sales and misrepresentations from a US broker dealer affiliate.

US July 2022: sales hit two-year low
North America | Products
30 Aug 2022 by SRP News

Both sales volumes and issuance suffered from the continued absence of Barclays.

Funds of structured products (part 2): the great turnaround
International | Products
25 Aug 2022 by Marc Wolterink

SRP did the rounds to see how the various funds of structured products performed in July.

Prudential flagship annuity reaches sales milestone
North America | Industry
18 Aug 2022 by Pablo Conde

The US demographic tailwind is providing an opportunity for insurance companies to offer market exposure and protected income.

Walmart delivers despite profit warning
North America | Industry
18 Aug 2022 by SRP News

Maturing products linked to the US multinational retail corporation delivered an average return of 20.56% pa and none returning a loss.

Finra fines J.P. Morgan over failures to address ‘red flags’ in structured products case
North America | Regulations & Legal
12 Aug 2022 by SRP News

The US regulator’s action against J.P. Morgan Securities is the latest case of unsuitable sales of structured products which exceeded the firm’s own limits.